PRA Health Sciences, Inc. (PRAH): Price and Financial Metrics


PRA Health Sciences, Inc. (PRAH)

Today's Latest Price: $99.15 USD

1.86 (1.91%)

Updated Sep 28 6:55pm

Add PRAH to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 58 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

PRAH Stock Summary

  • PRAH has a higher market value than 80.38% of US stocks; more precisely, its current market capitalization is $6,222,768,220.
  • PRAH's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 3,226 -- higher than 98.92% of US-listed equities with positive expected earnings growth.
  • In terms of volatility of its share price, PRAH is more volatile than only 9.89% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to PRA Health Sciences Inc, a group of peers worth examining would be PLXS, HURN, EV, CRL, and PRFT.
  • Visit PRAH's SEC page to see the company's official filings. To visit the company's web site, go to prahs.com.
PRAH Daily Price Range
PRAH 52-Week Price Range

PRAH Stock Price Chart Technical Analysis Charts


PRAH Price/Volume Stats

Current price $99.15 52-week high $113.32
Prev. close $97.29 52-week low $58.67
Day low $96.86 Volume 145,000
Day high $99.74 Avg. volume 420,085
50-day MA $103.35 Dividend yield N/A
200-day MA $98.20 Market Cap 6.34B

PRA Health Sciences, Inc. (PRAH) Company Bio


PRA Health Sciences provides various product development services for pharmaceutical and biotechnology companies worldwide. The company was founded in 1976 and is based in Raleigh, North Carolina.

PRAH Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$99.15$96.7 -1%

We started the process of determining a valid price forecast for PRA Health Sciences Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that PRA Health Sciences Inc ranked in the 44th percentile in terms of potential gain offered. In terms of the factors that were most noteworthy in this DCF analysis for PRAH, they are:

  • The company has produced more trailing twelve month cash flow than 59.95% of its sector Healthcare.
  • PRA Health Sciences Inc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than just 22.72% of tickers in our DCF set.
  • PRA Health Sciences Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at 5.69. This coverage rate is greater than that of 65.25% of stocks we're observing for the purpose of forecasting via discounted cash flows.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-3%
1%-2%
2%-1%
3%0%
4%1%
5%2%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as PRAH, try USPH, DXCM, DYNT, IART, and MOH.


PRAH Latest News Stream


Event/Time News Detail
Loading, please wait...

PRAH Latest Social Stream


Loading social stream, please wait...

View Full PRAH Social Stream

Latest PRAH News From Around the Web

Below are the latest news stories about PRA Health Sciences Inc that investors may wish to consider to help them evaluate PRAH as an investment opportunity.

PRA Health Sciences: A Solid Investment Case But Watch Out For Signs Of Inertia

Investment Thesis I last posted about PRA Health Sciences (PRAH) in May 2019, after the company's share price had slipped from late 2018 highs of $117 to trade at $90. I suggested that the company's days of sector and S&P beating growth - PRA's share price gained 216% between 2016...

Edmund Ingham on Seeking Alpha | September 21, 2020

PRA Health (PRAH) Enters Into Strategic Deal With Deep Lens

PRA Health's (PRAH) deal with Deep Lens can help detect and match oncology patients to suitable clinical trials and best precision therapies.

Yahoo | September 21, 2020

PRA Health Sciences and Deep Lens announce strategic relationship to accelerate patient recruitment for precision cancer trials

The two companies bring together cloud-based mobile technologies to improve the identification, screening and matching of patients to precision-based clinical oncology trials

GlobeNewswire | September 18, 2020

PRA Health Sciences Announces Appointment of New Director

RALEIGH, N.C., Sept. 15, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) today announced the appointment of Glen Stettin, M.D. to the Board of Directors of the Company, effective September 14, 2020. “We are delighted that Glen will be joining our Board of Directors.  With his widespread involvement in the healthcare field as both a physician and an executive, Dr. Stettin’s experience in innovation, data, analytics, technology and integrated health solutions will provide the Board with valuable insight as we continue to reinvent clinical research and make it more accessible to patients,” said Colin Shannon, President, Chief Executive Officer and Chairman of the Board of Directors of PRA Health Sciences, Inc.Dr. Stettin is Senior Vice President and Chief Innovation Offic...

Yahoo | September 15, 2020

Hedge Funds Dipping Their Toes Back Into PRA Health Sciences Inc (PRAH)

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the second quarter. You can find articles about an individual hedge fund's trades on numerous financial […]

Yahoo | September 14, 2020

Read More 'PRAH' Stories Here

PRAH Price Returns

1-mo -5.44%
3-mo 4.46%
6-mo 30.03%
1-year -0.08%
3-year 30.17%
5-year 155.15%
YTD -10.80%
2019 20.87%
2018 0.98%
2017 65.22%
2016 21.76%
2015 86.91%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7389 seconds.